Pentixather: paving the way for radioligand therapy in oncohematology

References

• Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708–2717. doi: 10.1182/blood-2006-07-035857
   PubMed Web of Science ®Google Scholar
• Bachet JB, Maréchal R, Demetter P, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol. 2012;23(9):2327–2335. doi: 10.1093/annonc/mdr617
   PubMed Web of Science ®Google Scholar
• Singh AJ, Gray JW. Chemokine signaling in cancer-stroma communications. J Cell Commun Signal. 2021;15(3):361–381. doi: 10.1007/s12079-021-00621-7
   PubMed Web of Science ®Google Scholar
• Bleul CC, Wu L, Hoxie JA, et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA. 1997;94(5):1925–1930. doi: 10.1073/pnas.94.5.1925
   PubMed Web of Science ®Google Scholar
• Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219–230. doi: 10.1016/j.ejca.2012.05.005
   PubMed Web of Science ®Google Scholar
• Arya M, Ahmed H, Silhi N, et al. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol. 2007;28(3):123–131. doi: 10.1159/000102979
   PubMedGoogle Scholar
• Huang EH, Singh B, Cristofanilli M, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231–236.
   PubMed Web of Science ®Google Scholar
• Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Front Oncol. 2020;10:1672. doi: 10.3389/fonc.2020.01672
   PubMed Web of Science ®Google Scholar
• Juntikka T, Vaittinen S, Vahlberg T, et al. Somatostatin receptors and chemokine receptor CXCR4 in lymphomas: a histopathological review of six lymphoma subtypes. Front Oncol. 2021;11:710900. doi: 10.3389/fonc.2021.710900
   PubMed Web of Science ®Google Scholar
• Ullah TR. The role of CXCR4 in multiple myeloma: cells’ journey from bone marrow to beyond. J Bone Oncol. 2019;17:100253. doi: 10.1016/j.jbo.2019.100253
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao F. Research progress of CXCR4-targeting radioligands for oncologic imaging. Korean J Radiol. 2023;24(9):871–889. doi: 10.3348/kjr.2023.0091
   PubMed Web of Science ®Google Scholar
• Osl T, Schmidt A, Schwaiger M, et al. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. Theranostics. 2020;10(18):8264–8280. doi: 10.7150/thno.45537
   PubMed Web of Science ®Google Scholar
• Schottelius M, Osl T, Poschenrieder A, et al. [177Lu]pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent. Theranostics. 2017;7(9):2350–2362.
   PubMed Web of Science ®Google Scholar
• Werner R, Haug A, Buske C, et al. CXCR4-targeted theranostics in hematooncology: opportunities and challenges. Nuklearmedizin. 2024;63(2):57–61. doi: 10.1055/a-2194-9965
   PubMedGoogle Scholar
• Herrmann K, Schottelius M, Lapa C, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather In advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med. 2016;57(2):248–251. doi: 10.2967/jnumed.115.167361
   PubMed Web of Science ®Google Scholar
• Lapa C, Herrmann K, Schirbel A, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7(6):1589–1597. doi: 10.7150/thno.19050
   PubMed Web of Science ®Google Scholar
• Maurer S, Herhaus P, Lippenmeyer R, et al. Side effects of CXC-Chemokine receptor 4-directed endoradiotherapy with pentixather before hematopoietic stem cell transplantation. J Nucl Med. 2019;60(10):1399–1405. doi: 10.2967/jnumed.118.223420
   PubMed Web of Science ®Google Scholar
• Lapa C, Hänscheid H, Kircher M, et al. Feasibility of CXCR4-dIrected radioligand therapy in advanced diffuse large b-cell lymphoma. J Nucl Med. 2019;60(1):60–64. doi: 10.2967/jnumed.118.210997
   PubMed Web of Science ®Google Scholar
• Dreher N, Dörrler AL, Kraus S, et al. C-X-C motif chemokine receptor 4-targeted radioligand therapy in hematological malignancies-myeloablative effects, antilymphoma activity, and safety profile. Clin Nucl Med. 2024;49(2):146–151. doi: 10.1097/RLU.0000000000004974
   PubMed Web of Science ®Google Scholar
• Buck AK, Grigoleit GU, Kraus S, et al. C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with advanced T-Cell lymphoma. J Nucl Med. 2023;64(1):34–39. doi: 10.2967/jnumed.122.264207
   PubMed Web of Science ®Google Scholar
• Al-Ibraheem A, Abdlkadir AS, Juweid ME, et al. FDG-PET/CT in the monitoring of lymphoma immunotherapy response: current status and future prospects. Cancers (Basel). 2023;15(4):1063. doi: 10.3390/cancers15041063
   PubMed Web of Science ®Google Scholar
• Filippi L, Dimitrakopoulou-Strauss A, Evangelista L, et al. Long axial field-of-view PET/CT devices: are we ready for the technological revolution? Expert Rev Med Devices. 2022;19(10):739–743. doi: 10.1080/17434440.2022.2141111
   PubMed Web of Science ®Google Scholar
• Park S, Parihar AS, Bodei L, et al. Somatostatin receptor imaging and theranostics: current practice and future prospects. J Nucl Med. 2021 Oct;62(10):1323–1329. doi: 10.2967/jnumed.120.251512
   PubMed Web of Science ®Google Scholar
• Filippi L, Di Costanzo GG, Tortora R, et al. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization. Nucl Med Commun. 2020;41(1):78–86. doi: 10.1097/MNM.0000000000001123
   PubMed Web of Science ®Google Scholar